New Drug Futures (Anti-Infectives)
Products that could change the Pharma market to 2010 and beyond
| Price: £695.00 Approx $1,349.69 (USD) €1,038.06 (EUR) |
|
|---|---|
| Overview: | |
| This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the anti-infective sector. The report includes unique sales forecasts by major product | |
|
This paper is available from one of our partner sites.
Click here for details and to download it. |
|
By Dr CL Barton / Publication Date: 19th May 2006
Contents:
NEW DRUG FUTURES
CURRENT MARKET SIZE 1
Antibiotic Sales .2
Antiviral Sales 2
Antifungal Sales .2
ADDRESSABLE PATIENT POPULATION 3
Bacterial Infections 3
Viral infections 3
Human Immunodeficiency Virus (HIV) .3
Hepatitis B (HBV) .4
Hepatitis C (HCV) .4
CURRENT TREATMENTS . 5
Antibacterial Agents .6
Antiviral Agents- HIV .6
Antiviral Agents- HCV/HBV ..7
ANTI-INFECTIVES SALES DRIVERS . 8
ANTI-INFECTIVE SALES BREAKERS .10
FUTURE TREATMENTS .11
MARKET DYNAMICS - WINNERS & LOSERS .15
KEY DRUGS LAUNCHES BY 2010 .16
KEY EVALUATION CRITERIA .17
KEY ANTI-INFECTIVES DRUG LAUNCHES BY 2010 18
Anidulafungin (Pfizer) 18
Novelty/rationale for mechanism of action .18
Proof of concept/clinical data 18
Management/clinical expertise .18
Competition within the marketplace/gaining share of voice .18
Risks associated with developing a drug within a therapeutic class 19
Filings and approval .19
Sales forecasts and assumptions .19
Competitor Ratio Analysis .19
Aptivus (Boehringer Ingelheim) .20
Novelty/rationale for mechanism of action .20
Proof of concept/clinical data .20
Management/clinical expertise .20
Competition within the marketplace/gaining share of voice 20
Risks associated with developing a drug within a therapeutic class .21
Filings and approval .21
Sales forecasts and assumptions .21
Competitor Ratio Analysis .21
Aplaviroc (GlaxoSmithKline) . 22
Novelty/rationale for mechanism of action .22
Proof of concept/clinical data .22
Management/clinical expertise .22
Competition within the marketplace/gaining share of voice 22
Risks associated with developing a drug within a therapeutic class 23
Filings and approval 23
Sales forecasts and assumptions .23
Competitor Ratio Analysis 24
Ceftobiprole (Johnson & Johnson). 24
Novelty/rationale for mechanism of action .24
Proof of concept/clinical data .24
Management/clinical expertise .25
Competition within the marketplace/gaining share of voice .25
Risks associated with developing a drug within a therapeutic class 25
Filings and approval .25
Sales forecasts and assumptions .26
Competitor Ratio Analysis .26
Garenoxicin (Schering-Plough) 26
Novelty/rationale for mechanism of action .26
Proof of concept/clinical data 26
Management/clinical expertise .27
Competition within the marketplace/gaining share of voice .27
Risks associated with developing a drug within a therapeutic class .27
Filings and approval .27
Sales forecasts and assumptions .27
Competitor Ratio Analysis 28
GW695634 (GlaxoSmithKline) . 28
Novelty/rationale for mechanism of action .28
Proof of concept/clinical data 28
Management/clinical expertise .28
Competition within the marketplace/gaining share of voice 29
Risks associated with developing a drug within a therapeutic class 29
Filings and approval .29
Sales forecasts and assumptions ..29
Competitor Ratio Analysis .30
Maraviroc (Pfizer) .30
Novelty/rationale for mechanism of action 30
Proof of concept/clinical data .30
Management/clinical expertise 30
Competition within the marketplace/gaining share of voice .30
Risks associated with developing a drug within a therapeutic class 31
Filings and approval .31
Sales forecasts and assumptions .31
Competitor Ratio Analysis .32
MK-0518 (Merck & Co) .32
Novelty/rationale for mechanism of action .32
Proof of concept/clinical data 32
Management/clinical expertise .33
Competition within the marketplace/gaining share of voice 33
Risks associated with developing a drug within a therapeutic class .33
Filings and approval .33
Sales forecasts and assumptions .34
Competitor Ratio Analysis .34
Retapamulin (GlaxoSmithKline) .34
Novelty/rationale for mechanism of action .34
Proof of concept/clinical data 34
Management/clinical expertise .35
Competition within the marketplace/gaining share of voice 35
Risks associated with developing a drug within a therapeutic class 35
Filings and approval 35
Sales forecasts and assumptions .35
Competitor Ratio Analysis .36
Telbivudine (Novartis) .36
Novelty/rationale for mechanism of action 36
Proof of concept/clinical data 36
Management and clinical expertise .36
Competition within the marketplace/ gaining share of voice 37
Risks associated with developing a drug within a therapeutic class .37
Filings & Approvals .37
Sales forecasts and assumptions .37
Competitor Ratio Analysis 38
TMC-114 (Johnson & Johnson/Tibotec Pharma) .38
Novelty/rationale for mechanism of action .38
Proof of concept/clinical data ..38
Management/clinical expertise .38
Competition within the marketplace/gaining share of voice 38
Risks associated with developing a drug within a therapeutic class 39
Filings and approval .39
Sales forecasts and assumptions .39
Competitor Ratio Analysis .40
Tygacil (Wyeth) 40
Novelty/rationale for mechanism of action .40
Proof of concept/clinical data .40
Management/clinical expertise .40
Competition within the marketplace/gaining share of voice .40
Risks associated with developing a drug within a therapeutic class .41
Filings and approval 41
Sales forecasts and assumptions .41
Competitor Ratio Analysis 41
Vicriviroc (Schering-Plough) 42
Novelty/rationale for mechanism of action ..42
Proof of concept/clinical data 42
Management/clinical expertise 43
Competition within the marketplace/gaining share of voice 43
Risks associated with developing a drug within a therapeutic class 44
Filings and approval .44
Sales forecasts and assumptions .44
Competitor Ratio Analysis .45
VX-950 (Vertex Pharmaceuticals) . 45
Novelty/rationale for mechanism of action .45
Proof of concept/clinical data 45
Management/clinical expertise .45
Competition within the marketplace/gaining share of voice .46
Risks associated with developing a drug within a therapeutic class .46
Filings and approval .46
Sales forecasts and assumption ..47
Competitor Ratio Analysis .47
Zeven (Pfizer) .47
Novelty/rationale for mechanism of action .47
Proof of concept/clinical data ..48
Management/clinical expertise .48
Competition within the marketplace/gaining share of voice .48
Risks associated with developing a drug within a therapeutic class .48
Filings and approval 49
Sales forecasts and assumptions .49
Competitor Ratio Analysis .49
COMPETITOR RATIO ANALYSIS SUMMARY .50
COMPETITOR RATIO ANALYSIS - COMPANIES .52